ALTAMIRA
ALTAMIRA: Phase II Trial of Acalabrutinib + Rituximab as First-line Treatment for Mantle Cell Lymphoma in Patients Aged ≥60 Yr

Released: December 12, 2024

Expiration: December 11, 2025

Activity

Progress
1
Course Completed